Full View

Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer

J Du, Y He, W Wu, P Li, Y Chen, Z Hu… - Journal of Pharmacy …, 2019 - academic.oup.com
Objectives Chemotheraputic drug resistance is a critical factor associated with the poor
survival in advanced/metastatic pancreatic cancer (PC) patients. Methods Human pancreatic …
被引用次数：27 相关文章

Targeting EphA2 with miR‐124 mediates Erlotinib resistance in K‐RAS mutated pancreatic cancer

J Du, Y He, W Wu, P Li, Y Chen, Z Hu… - Journal of Pharmacy …, 2019 - Wiley Online Library
Objectives Chemotheraputic drug resistance is a critical factor associated with the poor
survival in advanced/metastatic pancreatic cancer (PC) patients. Methods Human pancreatic …

Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer

J Du, Y He, W Wu, P Li, Y Chen… - The Journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
Objectives Chemotheraputic drug resistance is a critical factor associated with the poor
survival in advanced/metastatic pancreatic cancer (PC) patients. Methods Human pancreatic …

Targeting EphA2 with miR‐124 mediates Erlotinib resistance in K‐RAS mutated pancreatic cancer.

J Du, Y He, W Wu, P Li, Y Chen… - Journal of Pharmacy & …, 2019 - search.ebscohost.com
Objectives: Chemotheraputic drug resistance is a critical factor associated with the poor
survival in advanced/metastatic pancreatic cancer (PC) patients. Methods: Human …

Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer.

J Du, Y He, W Wu, P Li, Y Chen, Z Hu… - The Journal of Pharmacy …, 2019 - europepmc.org
Objectives Chemotheraputic drug resistance is a critical factor associated with the poor
survival in advanced/metastatic pancreatic cancer (PC) patients. Methods Human pancreatic …